Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
Launched by CAPITAL MEDICAL UNIVERSITY · Sep 29, 2009
Trial Information
Current as of June 23, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 65ys≥age≥18ys
- • renal transplant recipients
- Exclusion Criteria:
- • subjects with hypersensitivity to amphotericin B
- • receipt of inhalational or intravenous amphotericin B within last 30 days
- • subjects with known invasive fungal infection before renal transplant
- • subjects with pneumonia
About Capital Medical University
Capital Medical University is a leading institution in medical education and research, dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on scientific rigor and ethical standards, the university collaborates with a network of healthcare professionals and researchers to drive breakthroughs in medical science. Capital Medical University aims to enhance patient care and improve health outcomes by fostering a multidisciplinary approach to clinical research, ensuring that its trials are designed to address critical health challenges and contribute valuable insights to the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials